Monday, June 1, 2020

News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights

It was my pleasure and an honor to be named one of ASCO's Featured Voices for this year's annual meeting. 

Over the course of the next few days I will be highlighting the research studies presented at the #ASCO20 Virtual Annual Meeting. I will share  posters, oral abstracts and presentations on gynecologic oncology, survivorship, cancer disparities and the impact of COVID 19 on cancer patients . I will also share parts of ASCO President Skip Buris's address and the keynote address by author, physician and cancer survivor Dr David Fajgenbaum. 

Since my Voice was active on Twitter I will share the tweets I wrote as well as ones I retweeted.

Today, I will begin with gynecologic cancer studies.

Surgery on Recurrence - Ovarian Cancer
Abstract 6000
Patients with surgery and incomplete resection had worse outcomes (median 28.8 months).   meetinglibrary.asco.org/record/185438/


Abstract 6001

PFS was 18.1 m vs 13.6 m in favor of the surgery arm #gyncsm #ASCO20 #OVCA Dr R Zang


 If you want to learn more head over to this YouTube video ( https://youtu.be/22UFGOGZ9lI )  featuring Dr Coleman's ASCO “Dissecting Out Improved Outcomes.” via  #SGOatASCO.

PARP Inhibitors - Ovarian Cancer
Abstract 6002

Olaparib w/ Cediranib - Ovarian Cancer
Abstract 6003

This was an all oral non-platinum treatment trial. Cediranib is a tyrosine kinase inhibitor for VEGFR1,2,3. Protocol was amended to allow maintenance therapy.

Folate receptor - Ovarian Cancer
Abstract 6004

Ovarian Cancer exhibits a folate receptor alpha (FRα). Adverse Events included diarrhea , blurred vision , nausea , and fatigue. Dr Gilbert presented.

Pembolizumab PD-1 - Ovarian Cancer
Abstract 6005 

If you can learn more about these studies by watching this video of Dr. Banerjee’s presentation, “Stay Sharp on PARP and More.” #SGOatASCO  https://youtu.be/ZTUyn8vPZ2Q

Olaparib LIGHT Study - Ovarian Cancer
Abstract 6013


Imaging with PARP inhibitor - Ovarian Cancer
Abstract 6014

BRCA1/ 2 Testing Ovarian Cancer
Niraparib and bevacizumab Ovarian Cancer
Abstract 6012

Immunotherapy Clear cell OC
Abstract #302065

Interesting I/O poster by Klein et al. Abstr #302065
Volunteers: All with rare gyn cancers (n=43)
Intervention: Ipi+Nivo
Comparator: NA
Outcome: ORR 28%
*Clear cell cancer (n=6): ORR 33% (1 CR seen)#gyncsm #ASCO20


Cervical Cancer
Abstract 6007



There are many more abstracts and posters related to gyn cancers available in the ASCO Meeting Library.

Dee
Every Day is a Blessing!

No comments: